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Abstract
FGF23 is a novel phosphaturic hormone; we aimed to assess the FGF23 levels and its association with dietary
phosphate intake and indices of renal handling of phosphate in this study. Prospective study was conducted in which
dietary phosphate intake was assessed by food frequency questionnaire (FFQ) along with blood and spot urine samples
were collected after overnight fast for determining serum phosphate, FGF23, fractional excretion of phosphate (FePO4)
and tubular maximum for phosphate (TmP/GFR). FGF23 (C-Term) was measured by a sandwich ELISA.
The mean dietary phosphate intake of eighty healthy adults (mean age of 29 ± 5 years) was 1220 ± 426 mg; median
FGF23 was 49.9 RU/ml (IQR=33, 76) and mean FePO4 was 7 ± 4.7. Subjects were stratified into two groups according
to serum phosphate levels. Significant difference was not found in dietary phosphate intake and FGF23 levels in the
two groups. However, TmP/GFR and creatinine were significantly different in the two groups. FePO4 was high in both
the groups.
Overall a rising pattern of FGF23 levels was seen with increasing serum phosphate levels. Significant positive
correlation was found between FGF23 and dietary phosphate (r=0.22, p<0.05) and negative correlation was seen
between FGF23 and FePO4 (r=-0.260, p<0.05).

Keywords: Phosphate; FGF23; TmP/GFR; 1, 25(OH)2 Vitamin D;

FePO4

Introduction
Fibroblast 23 (FGF23) is primarily expressed in osteocytes and
in endothelial cells lining the venous sinusoids of bone marrow and
thymus [1]. Most of its functions occur in the kidney through an FGF
receptor (FGFR)/Klotho complex; and it acts opposite to vitamin D
by inhibiting 1 alpha hydroxylase and stimulating 24 hydroxylase
enzymes in the renal tubule. As a result, 1,25 OH vitamin D catabolism
is increased with decrease in production due to excess of FGF23 [2].
Moreover, the expression of type II sodium-dependent phosphate cotransporters (mainly NPT2a and NPT2c) is inhibited by FGF23 in cells
of renal proximal tubules which reduces phosphate reabsorption and
consequently increases urinary phosphate excretion.
FGF 23 also interacts negatively with PTH mRNA in contrast
to CKD, where increased FGF23 is associated with secondary
hyperparathyroidism. Due to these opposing verdicts; local and
systemic confounding factors have been projected to modify FGF23
levels and taken together, it is advocated that PTH and FGF23 axis is
similar to vitamin D-FGF23 loop [2].
Another main stimulus for FGF23 released is increased phosphate
intake as evinced by the literature, as FGF23 levels were not increased
by the rise in serum phosphate levels due to non-dietary interventions
[3]. Literature showed that consumption of diet low in calcium and
high in phosphorus have detrimental effects on the normal physiology
of peak bone mass which leads to osteoporosis in later life. Both short
term and longer consumption of phosphate causes increase in PTH
levels and thus increases bone turnover. On the other hand despite
minor rise in PTH levels, calcitriol showed a significant reduction or
no change in concentrations.
As FGF23 is a novel regulator of phosphate homeostasis and its
has actions on PTH and 1,25 (OH)2 D metabolism and is considered
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key factor in bone cellular, metabolic, and mineralization functions.
Hence, both over and under expression of FGF23 results in negatively
affecting bone mineralization; while its deficiency leading to severe
hypophosphatemia, hyper vitaminosis D, and increased circulating
calcium [2]. The extra renal functions of FGF23 are important apart
from renal failure, as the association of FGF23 with adversative
outcomes including cardiovascular changes is sturdier.
Studies showed that higher FGF23 levels are now associated
with cardiovascular complications and death. Association of FGF23
concentrations with adversarial outcomes is stronger in patients with
CKD as it is not captured by measurement of routine biomarkers for
CKD i.e., eGFR or albuminuria [3].
FGF23 has not been studied in our population. We presumed that
FGF23 is high in our subjects due to high dietary phosphate intake [4].
This has implications for the bone health and diagnosis and treatment
of phosphate-wasting disorders and vitamin D metabolic defects. The
purpose of this study was to explore FGF23 levels in healthy subjects
and assess its relationship with serum phosphate; TmP/GFR, FePO4
and dietary phosphate.
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Materials and Methods
A prospective cross sectional study took place at Section of Clinical
Chemistry, Department of Pathology and Laboratory Medicine, Aga
Khan University, Karachi. The study was reviewed and accepted by the
Ethical Review Committee, Aga Khan University Hospital.
Healthy subjects of either gender staff were recruited after informed
consent. A performa including the demographics age, gender, ethnicity,
occupation was filled at the time of drawing blood.
Blood sample was taken from study subjects after an overnight
fast, in ethylene diamine tetra acetic acid (EDTA) and gel tubes for
analysis of FGF23 and serum phosphate and creatinine respectively.
At the same time subjects were asked to provide a spot urine sample
for phosphate and creatinine measurements. Plasma was collected after
centrifugation at 3000 rpm for 5 min. Aliquotting of plasma samples
was performed, and tubes were labeled and kept at -70°C till analysis of
plasma FGF23, serum creatinine and phosphate.
Dietary information was recorded on food frequency questionnaires
(FFQ) through a face-to-face interview with the principal investigator,
and the duration of each interview took about 20 to 25 minutes. The
FFQ was previously validated [5]. The raw composition of phosphate
content in each food item was taken from the U.S. Department
of Agriculture, Agricultural Research Service, and Nutrient data
laboratory. In certain cases where this information was not available
from the USDA, other local food composition tables were consulted
[6]. Dietary data for phosphate content were totaled by multiplying the
intake frequency of each food item by the phosphate content of the
given portion sizes.
FGF23 levels (C-term) were measured by a sandwich enzyme
linked immunosorbent assay (ELISA) from Immunotopics Inc. (San
Clemente, California). Both normal and abnormal control materials
were run to assure quality of analysis. The normal reference range for
plasma FGF23 was taken as median 52.4 RU/ml [4,7,8].
Plasma and urinary phosphate and creatinine levels were measured
by Synchron CX9 by Beckmann instruments Brea, California USA
based on spectrophotometric principle. To ensure quality, two levels of
controls (normal and abnormal) were run with each batch of plasma,
serum and urinary phosphate and creatinine analysis. The laboratory
participated in external proficiency testing from BIORAD laboratories
California, USA for phosphate and creatinine every three months.
Values for serum phosphate, serum creatinine, urinary phosphate
and creatinine were utilized for derivation of FePO4 and TmP/GFR by
using these formulae [9]:
=
TmP / GFR
FePO 4=

SPO4 –

( U PO4 × Scr )

( U PO4 × Scr / U cr )
/ ( SPO4 × U cr ) × 100%

Normal range for TmP/GFR was 2.4-4.8 mg/dl and cutoff for
normal FePO4 was taken as <5%.
SPSS version 19 was used to compute and analyze the data.
Frequencies of gender were generated. Means and standard deviations
for continuous variables (age, serum FGF23, serum and urinary
phosphate and serum and urinary creatinine) and proportion for
categorical variables (gender, ethnic origin, and education) was also
computed. A confidence interval of 95%, for the FGF23 was reported.
Data of FGF23 was skewed so median value was reported along with
interquartile ranges. We had also compared two groups of serum
phosphate using Mann-Whitney U Test and association between
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log transformed FGF23, serum phosphate, dietary phosphate, serum
creatinine, FePO4 and TmP/GFR using spearman’s correlation
coefficient.
Effect modifiers were controlled through age, gender, serum
phosphate; dietary phosphate, FePO4, serum creatinine and TmP/
GFR to see the impact on the outcome variable. A p-value of <0.05 was
considered as significant and p value<0.01 as highly significant in all
statistical analysis.

Results
Eighty subjects were recruited in the study. The mean age of the
study subjects was 29 ± 4.7 years with 51% (n=41) being females.
Table 1 shows the anthropometric details and biochemical parameters
assessed in study subjects.

Relation of serum phosphate with FGF23 and indices of renal
handling
Only one subject had high serum P (>4.5 mg/dl), with high dietary
phosphate intake (1685.6 mg) and high FePO4 (8.5%) and FGF23 levels
of 54.9 RU/ml. This subject was excluded from final analysis.
Table 2 shows indices of renal handling, dietary phosphate
intake and FGF23 levels in 79 subjects with low and normal serum
phosphate levels. Six subjects (11%) were identified to have low mean
serum phosphate levels (2.3 ± 0.2 mg/dl), the cause of which is not
known. Mean TmP/GFR was low and FEPO4 was high in subjects with
hypophosphatemia. FGF23 concentrations were increased in only 2
subjects, while the rest have levels less than the cut off.
Creatinine and TmP/GFR were significantly different between
subjects with low and normal serum phosphate levels.

Distribution of FGF23 and association with indices of renal
handling
Log FGF23 showed a statistically significant negative correlation
with serum creatinine (p<0.05) and FEPO4 (p<0.05). Significant
association was not found with serum PO4, dietary phosphate and
TmP/GFR (Table 3). However, with increase in median FGF23
quartiles, a downward trend is seen in serum phosphate and TmP/GFR
and upward trend in FePO4 (Tables 4 and 5).
Gender
Male
Female

49% (n = 39)
51% (n= 41)

Mean Age
(Yrs.)

29 ± 4.7

Mean BMI
(kg/m2)

22.98 ± 3.91

Mean Serum PO4
(mg/dl)

3.35 ± 3.91

Mean TmP/GFR
(mg/dl)

3.04 ± 0.57

Mean FePO4
(%)

7.0 ± 4.7

Mean Dietary
Phosphate
(mg)

1220 ± 426

Median FGF-23
(RU/ml)

49.9 (33-76.1)

Abbreviations used: BMI, Body Mass Index; FGF-23, Fibroblast growth factor 23;
TmP/GFR, Tubular maximum re-absorption of phosphorus per unit of GFR; PO4,
Phosphate; FePO4, fractional excretion of Phosphate.
Table 1: Demographic, Dietary Phosphate Intake and Biochemical Characteristics
of Study Subjects (n=80).
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Serum Phosphate

p-value

<2.5 (n=6)

2.5 to 4.5 (n=73)

FGF23 (RU/ml)

52.3
(IQR = 31.8 to 75.3)

48.6
(IQR= 32.3 to 81.6)

0.988

TmP/GFR
(mg/dl)

2.1 ± 0.22

3.1 ± 0.47

0.000***

Dietary Phosphate
Intake (mg)

1174 ± 519

1219 ± 416

0.563

FePO4 (%)

7.9 ± 4.1

9.1 ± 4.7

0.468

Serum Creatinine
(mg/dl)

0.6 ± 0.2

0.8 ± 0.2

0.033*

*p-value<0.05
***p-value<0.001
Groups were compared by using Mann-Whitney U test. There is significant
difference between TmP/GFR and serum creatinine between the two groups.
FGF-23, Fibroblast growth factor 23; TmP/GFR, Tubular maximum re-absorption
of phosphorus per unit of GFR; PO4, Phosphate; FePO4, fractional excretion of
Phosphate.
Table 2: Indices of Renal Handling, Dietary Phosphate Intake and FGF-23 In
Subjects With Low and Normal Serum Phosphate Levels (n=79).

Independent Variables
(X)

Dependent Variable (Y)
FGF23
β

P

Gender

-0.11

0.038

BMI

-0.01

0.157

0.00086

0.698

S. Phosphate

-2.18

0.245

S. Creatinine

-1.44

0.009

TmP/GFR

2.62

0.084

FePO4

0.12

0.019

Dietary Phosphate Intake

R2

0.598 i.e.,
59.8%

The regression coefficient β and P values for potential determinants (X) i.e.
Gender. S. Creatinine and FePO4 of FGF23 was positively associated and changes
in response to FGF23 levels in healthy individuals. It was calculated by multiple
regression analysis in 80 subjects and R2 showing good regression of FGF23 i.e.
59.8%. FePO4, fractional excretion of phosphate. Significant P values are shown
in bold.
Table 3: Correlates between FGF23 and indices of renal handling.
Median FGF23
Quartile 1
32.6

Quartile 2
49.3

Quartile 3
73.9

Age

26

30

36

S. PO4

3.5

3

2.1

S. CR

0.8

0.5

0.9

FEPO4

6.87

8.79

16.58

TmP/GFR

3.26

2.74

1.75

TPO

1588.24

1305.87

1588.24

Table 4: Distribution of dietary phosphate and indices of renal handling with
median FGF23 quartiles.
Study Year Author

Study Subjects

Discussion
FGF23 is a bone-generated major regulator of phosphate
homeostasis. It is identified in healthy individuals and its level in our
population is comparable with those reported in literature on healthy
subjects from other population. Similar findings are seen in the 25
healthy Swiss subjects with high phosphate intake of 1400 ± 100 mg,
median FGF23 of 48.3 ± 4.6 RU/ml and serum phosphate of 3.90 ± 0.09
mg/dl (Table 4).
This is the first study from Pakistan that has determined plasma
FGF23 levels in healthy subjects. Median plasma FGF23 in apparently
normal healthy subjects is 49.9 (IQR=33-76.1), at serum phosphate
of 3.3 ± 3.91 mg/dl and dietary phosphate intake of 1220.3 ± 426.4
mg. Plasma FGF23 was not different between the low and normal
phosphate group. Increased FePO4 is seen in the subjects, most likely to
be due to high dietary phosphate intake.
Significant association was not found which may be due to
small sample size. In addition, parathyroid hormone levels were not
measured which has positive effect on urinary phosphate excretion.
High PTH is a frequent finding in our population due to prevalent
vitamin D deficiency [10].
Serum phosphate homeostasis is a dynamic process and its vivo
levels are balanced by a coordinated process including phosphate gut
absorption, preservation and efflux of bone and cellular phosphate
along with the urinary excretion from the kidneys. It is done mainly
by kidneys which maintain serum phosphate levels by controlling its
excretion stimulated by changes in dietary pattern of phosphate. Most
of the phosphate load is cleared by kidneys and it is considered a vital
organ in maintaining the phosphate homeostasis.
Literature showed that disorders of phosphate metabolism are
risk factors for cardiovascular complications and these findings lead
to phosphate intake restrictions as part of treatment for the enhanced
prognosis in patients with cardiovascular diseases as increased
phosphate intake was the main causative factor in the studied
population. The novel mediators of phosphate metabolism i.e., FGF23
and klotho are linked to dietary phosphate intake and are integral
markers of phosphate overload and its bad prognosis.
Furthermore, serum phosphate was weakly associated with FGF23 and it was also not statistically significant in our healthy volunteers
whereas a significant correlation was seen with FePO4 and serum
creatinine. Westerberg et al. also showed negative linear correlations
between FGF23 and phosphate and between FGF23 and TmP/GFR was
borderline significant in their small sample done on healthy donors
before nephrectomy [11]. Recent literature showed special focus on
FGF23 and its association with phosphate homeostasis and vitamin D
abnormalities in patients with chronic renal failure.

Population FGF-23 levels

Other Parameters included

2003

Jonsson et al. [22] 141 adult

Caucasians 55 ± 50 RU/ml

Normal Phosphate

2003

Weber et al. [4]

Caucasians Median 13 RU/ml (5 to 210) Ca2+ 9.5 ± 0.1 mg/dl, PO4 3.7 ± 0.1mg/dl, median creatinine 0.9 (0.61.3) mg/dl, median iPTH 34 (11-77).

2005

Ferrari et al. [24] 29 healthy males

Swiss

48.3 ± 4.6 RU/ml

Serum Phosphate 3.90 ± 0.09 mg/dl, PO4 intake 1400 ± 100 mg, TmP/
GFR 3.57 ± 0.09 mg/dl, PTH 26 ± 2.1 pg/ml, 1, 25 OH vit D 37.5 ±
1.0 pg/ml.

2009

Laroche et al.[12] 15 adults

French

39.1 ± 16.4 RU/ml

Serum phosphate 3.2 ± 0.5 mg/dl, PTH 21 ± 8 pg/ml, Ca2+ 9.7 ± 0.8
mg/dl

2015

Abbas et al.

Pakistani

Median 49.9 RU/ml (33-76.1) Serum phosphate 3.35 ± 3.91 mg/dl, dietary Phosphate 1220 ± 426
mg, TmP/GFR 3.04 ± 0.57 mg/dl, FePO4 7.0 ± 4.7%

42 adults

80 healthy adults

Table 5: Various studies reporting FGF-23 levels in healthy controls.

J Nanomed Nanotechnol
ISSN: 2157-7439 JNMNT, an open access journal

Volume 7 • Issue 1 • 1000348

Citation: Abbas N, Khan AH, Ghani F, Siddiqui I (2016) Fibroblast Growth Factor 23 (FGF23) Levels, Phosphate Intake and its Association with
Indices of Renal Handling of Phosphate in Healthy Volunteers. J Nanomed Nanotechnol 7: 348. doi:10.4172/2157-7439.1000348

Page 4 of 4
Our study has some limitations, first of all, small sample size of the
study, which limits the applicability of our findings to other studies.
Secondly, we have not assessed the vitamin D, serum calcium levels and
PTH in this study which is another well described biologic modifiers of
FGF23 i.e., it inhibits 1α-hydroxylation of leading to low levels of 1,25
(OH)2 D. These findings are significant in our population where there is
a high risk of bone diseases due to increased high incidence of vitamin
D deficiency [12,13] and use of a diet which is rich in phosphate
and low in calcium. Moreover, Recently FGF23 is also connected to
hypertension, obesity and metabolic syndrome which are prevalent in
our population. If such data can be authenticated in our population
settings, this would represent a key paradigm move that changed
FGF23 from biomarker to mechanism of disease, and raises the option
of FGF23 being a primary target for intervention.
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